Following the recommendation against PSA screening by the U.S. Preventative Services Task Force (USPSTF) a number of organizations and doctors spoke out criticizing the statement. Many of the criticisms are directed at a perceived misunderstanding, by those who conducted the study, of the value of the current test in practice. Some argue that there’s no question that PSA screening has resulted in fewer cancer deaths since testing has been in place, yet the current findings call into question the value of the biomarker itself.
